@article{59882d8648e949d18ccef0776a527055,
title = "Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion",
abstract = "Introduction: Synchronous oligometastatic non-small cell lung cancer (NSCLC) definition varies from 1 metastasis in 1 organ (tumour-node-metastasis 8 [TNM8]), 1-3 metastases (European Society for Medical Oncology [ESMO]),Methods: In December 2017, 10 real-life multidisciplinary team (MDT) discussed patients (good condition, no significant comorbidities, F-18-fluorodeoxyglucose positron emission tomography/brain magnetic resonance imaging staged, all <5 metastases, 9/10Results: Twenty-six of 33 experts (24 centres) replied: 8 medical oncologists, 7 pulmonologists, 7 radiation oncologists, 4 thoracic surgeons. Sixty-two percent of respondents discussed the cases with their MDT. One case had 100\% oligometastatic consensus, and 3 cases had >90\% consensus; the number of treatment proposals varied between 3 and 8. Radical treatment was more often offered in case of single metastasis or N0. Compared with 2012, there was a trend towards a more conservative oligometastatic definition and chemotherapy was more frequently included in the treatment proposal.Conclusions: Oligometastatic NSCLC definition was conservative. The number of organs, MLN status and radical treatment possibility seem to be components of daily practice oligometastatic definition. (C) 2019 Elsevier Ltd. All rights reserved.",
keywords = "NSCLC, Oligometastatic, Definition, Case-based survey, NSCLC FOLLOWING COMPLETION, TNM STAGE GROUPINGS, PHASE-II, ADRENAL METASTASES, RADIATION-THERAPY, RADICAL TREATMENT, PROGNOSTIC VALUE, OUTCOMES, PROJECT, CLASSIFICATION",
author = "Hendriks, \{Lizza E. L.\} and Christophe Dooms and Thierry Berghmans and Silvia Novello and Antonin Levy and \{De Ruysscher\}, Dirk and Baktiar Hasan and Levra, \{Matteo Giaj\} and Levra, \{Niccolo Giaj\} and Benjamin Besse and Johan Vansteenkiste and Dingemans, \{Anne-Marie C.\} and \{European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group\}",
note = "Funding Information: This publication was supported by a donation from the {\textquoteleft} Kankerbestrijding/KWF {\textquoteright} from the Netherlands through the EORTC Cancer Research Fund. The funding source had influence whatsoever on design, collection, analysis and writing of the manuscript. Funding Information: T.B. reports no conflict of interest regarding the content of this manuscript. A.L., N.G.L., J.V., B.H., M.G.L. and C.D. report no conflict of interest. L.E.L.H. reports no conflict of interest related to the current manuscript. Outside of the current manuscript L.E.L.H. received research funding from Roche and Boehringer Ingelheim (both institution); has been a member of the advisory board of Boehringer and BMS, (both institution, BMS also self); has received travel reimbursement from Roche and BMS (self); has participated in a mentorship program with key opinion leaders funded by AstraZeneca and has received fees for educational webinars from Quadia (self). S.N. reports no conflict of interest related to the current manuscript. Outside of the current manuscript, S.N. has been a member of the advisory board of Abbvie, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, MSD, Takeda, Roche and Pfizer. D.D.R. reports no conflict of interest related to the current manuscript. Outside of the current manuscript, D.D.R. has been a member of the advisory board of AstraZeneca, Bristol-Myers Squibb, Roche/Genentech, Merck/Pfizer, Celgene, Noxxon and Mologen and has received investigator-initiated grants from Bristol-Myers Squibb and Boehringer Ingelheim. A-.M.C.D. reports no conflict of interest related to the current manuscript. Outside of the current manuscript, A-.M.C.D. has been a member of the advisory board of BMS, MSD, Roche, Eli Lilly, Takeda, Pfizer, Clovis, AstraZeneca, AbbVie and Boehringer Ingelheim (all institution) and reports receiving grant from BMS (institution). B.B. reports no conflict of interest related to the current manuscript. Outside the current manuscript, B.B. received grants for clinical and translational research from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda and Tiziana Pharma.This publication was supported by a donation from the ?Kankerbestrijding/KWF? from the Netherlands through the EORTC Cancer Research Fund. The funding source had influence whatsoever on design, collection, analysis and writing of the manuscript. Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",
year = "2019",
month = dec,
doi = "10.1016/j.ejca.2019.09.013",
language = "English",
volume = "123",
pages = "28--35",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
}